text:
Polaris North Star Ring in Moissanite / Diamond | R3008
As the brightest star in the constellation Ursa Minor, the Polaris is known for holding nearly still while the entire northern sky moves around it, always steady, trustworthy, and reassuring even when the darkest night falls. Meant for the guiding star in your life, our Polaris series invites you to hold each other's hands, and re-write the future skyscape together.
Product Details
Main Stone Options:
- 6.5mm*6.5mm / 1.0 carat Forever One Moissanite (D-F color, VS Clarity, C&C certificate included)
- 1.0 carat Lab Diamond (G+ color, VSII Clarity minimum; IGI certificate included)
- 1.0 carat Natural Diamond (G+ color, VSII Clarity minimum; GIA certificate included)
From the drop-down menu, you may select desired center stone choice based on your preference. To ensure the authenticity of our materials and gemstones:
All moissanite center stones come with a C&C certificate.
All lab diamond center stones come with an IGI certificate.
All natural diamond center stones come with an GIA certificate.
We are able to accommodate additional custom requests including:
- Different center stone sizes (smaller or bigger)
- Diamond center stone upgrades for color or clarity
Accent Stones:
100% Genuine Diamonds, VS Clarity, G Color
- This listing sells only the main ring in the listed gemstone(s) above; other jewelry pieces shown are for styling reference only. For band pairing options, please visit the "suggested pairing" section below.
- Whenever possible, we recommend purchasing the main ring and the matching band(s) at the same time to ensure a perfect fit.
Our customization services include center stone change, accent stone change, and/or design modifications. We offer additional gemstone options such as diamond center stones (GIA or IGI certified), Australian opals, natural colored sapphires, natural emeralds, amethysts, or any other gemstone of your choice.
If you are interested in one of our settings but prefer to use your own center stone, semi-mount purchase options are available upon request.
Engraving is complimentary for all orders over $1000 USD; please simply leave us a note at checkout with your preferred engraving text. If your order total is less than $1000 USD, you may purchase engraving service for an additional $50 fee here.
Visit our Custom & Bespoke page for more information, or email us to get started on the customization process!
Suggested Pairings
Shipping & Delivery
We take pride in handcrafting each piece of Michellia jewelry with great love and care. Unless otherwise specified on the product page or shop annoucement section, please allow 6-8 weeks for custom production plus transit time. We ship both domestically and internationally via Fedex with tracking and signature confirmation. Read more about Shipping.
If you have a specific timeline to meet, please kindly place the order at least one and half (1 1/2) months prior to your desired delivery date. If you live outside of the U.S, we recommend that you place your order two (2) months prior to your desired delivery date to account for potential delay in the custom clearance process.
If you have an urgent deadline to meet (less than 5 weeks), please first check out our ready-to-ship collection. If you do not see your preferred item(s) in our ready-to-ship collection, please email us with your detailed requests for additional inventory availability.
Returns & Exchanges
Every effort will be made to ensure your satisfaction with your Michellia purchase. We accept returns and exchanges on most orders within 30 days of initial delivery. Since each piece of Michellia Jewelry is individually handcrafted to order, all returns (excluding ones related to craftsmanship defects) will incur a 30% restocking fee. If you wish to exchange your piece, we can apply the full amount of your original purchase to a new purchase of equal or greater value (limit one exchange per customer). A one-time $100 exchange fee will be charged for all exchanges to cover additional shipping & handling.
Exceptions & Exclusions:
- Orders wih diamond center stones (lab or natural) cannot be returned or exchanged, but can be altered, resized, or serviced under the same warranty as other non-diamond center stone items.
- Ready-to-ship items cannot be returned, but enjoy the same exchange policy as above.
- Sale items are not eligible for returns or exchanges, but can be altered, resized, or serviced under the same warranty as regular-priced items.
- Orders placed between October 1st and November 11th will enjoy extended holiday return & exchange window of 60 days.
Read more about Returns & Exchanges.
Customer Care
We stand behind the quality of all Michellia jewelry and provide lifetime warranty against all craftsmanship defects. Please read about our Lifetime Warranty.
If you have any additional questions, please visit our Customer Care page, or email us at email@example.com.
Complete the Set
Even better than anticipated
I was a bit nervous with choosing this design for my now fiancé's ring as it isn't very orthodox. However, I was thoroughly surprised by how amazing it looked when it came in person. Michellia has had great customer support responding timely and in a helpful way. Their packaging and box that came with the ring was also very good quality! Highly recommend


text:
Dear visitor,
Since its inception Vodafail.com has made a significant
contribution towards raising awareness of the problems and issues faced
by Vodafone customers.
Vodafone Australia customers have had the opportunity to voice their concerns, their fears and their troubles from every corner of Australia and beyond our borders.
You have gathered the courage to stand up for your rights as consumers and to make your voice heard.
Each and every person who shared their story should have a sense of pride in this achievement and the changes that have occurred since the start of Vodafail.com.
More recently, traffic to Vodafail.com has declined significantly.
Having achieved the goal of raising awareness and promoting concrete action in early 2011, we have now reached the point of closing Vodafail to new complaints.
The site will remain online for as long as possible as a
reminder and an example of what is possible when we share our experiences.
It has been a privilege to run this initiative
and I'm am forever grateful for the help and support I've received. In
particular I would like to thank Melissa, David and Travis for their
continued efforts over the past 15 months. I'm also thankful and humbled by the support of ACCAN, Choice magazine and a wide range of media outlets, blogs and websites.
You can still browse existing stories and find out how to file a complaint if you are experiencing problems.
Until next time,
Adam Brimo
Share Your Pain
|Everywhere (19206)
|Somewhere else (224)
4483 Someone from QLD thinks vodafone is Intermittent reception at 27 Dec 2010 06:14:06 PM
Visited Blackburn Victoria recently, no reception. Went to Vodafone shop, they changed my SIM but no help. I live at Buderim in Qld, no reception in King Street, one of the main streets. Reception is sketchy to say the least.

subset: commoncrawl


text:
Lost in Translation: Doing Business Internationally
April 15, 2016
Hosted by Marcia Zidle
[Download MP3s: Full Show Marcia's Musings] [itunes] [Bookmark Episode]
Guest Information
Episode Description
When doing business on an international stage, it's crucial to not only know what to say, but how to say it. Whether you're the CEO or an envoy for a company doing global business, Pamela Eyring shares how a working knowledge and comprehension of the cultural, business and social customs of your international associates can ensure that nothing is lost in translation.
The Business Edge
Archives Available on VoiceAmerica Business Channel
Your entrepreneurial vision has taken hold. Your business is growing. It's everything you hoped for and more. Or is it? With growth come bigger headaches: more hiring, more capital, more customers to satisfy, more employees to deal with, more plates to juggle and more demands on your time. Whether you realize it or not, you are experiencing Growing Pains!
On The Business Edge, with host Marcia Zidle, The Smart Moves Coach, you will hear how to make the leap from running a stressful business that is always putting out fires to leading a successful company that operates like a finely tuned management machine. You will meet savvy, street smart entrepreneurs and business leaders who'll share their stories of success and even missteps as well as practical solutions to the unique challenges faced by growing companies.
Marcia Zidle
Marcia Zidle, The Smart Moves Coach, works with entrepreneurial ventures and small to medium size companies to build and leverage their leadership foundation to move from Start-Up to Scale-Up to Successful Enterprise. In other words, she helps them take the growing pains out of growth.
Coming from a unique entrepreneurial and corporate background, she's both street smart and strategic as she guides CEO's and their management teams to focus on the right priorities - the right talent - the right alignment - the right performance to get the right results that will satisfy their investors, customers and other stakeholders.
With 25 years of management, business consulting and international experience, she brings an expertise in executive and team leadership; employee engagement and performance; personal and organization change; emotional and social intelligence. Her clients range from privately owned businesses to mid-market professional firms to divisions of global companies in the following industries: healthcare, financial services, insurance, manufacturing, transportation, high-tech, hospitality as well as governments and nonprofit agencies.
Marcia's "claim to fame" is as a global citizen, living as an expatriate with her family in Scandinavia and Australia. In fact, one of her children is an "Aussie." She's traveled in over 30 countries throughout Europe, the Middle East, Far East and South Pacific.


text:
164 inquiries
Construction Clean Up Service Contractors
(909) 797-7550
Company Rating
Customer Reviews
based on 0 reviews.
Write Review
Complaint Experience
Membership Information
This business is not a member of Business Consumer Alliance. This fact does not disparage the company in any way.
Recent Review
This business has no reviews.
BCA's Summary and Analysis:
We have received no complaints against this company.
Read More
Our complaint services are free and our team of expert mediators will assist in resolving complaints with businesses.
File Complaint
Complaint Closing Statistics
Company Info
This company's nature of business is under review
Is this Your Business?
Claim Business
Sign up for a Business Consumer Alliance account to manage your online storefront and complete your company's profile.
Learn More
Interested in Alpha Omega Construction Clean-Up?
Contact them directly!
Request Quote
We know of no licensing or registration requirement for companies engaged in this company's stated type of business.
BCA has no information regarding government actions at this time.
We have no further comment about this company's business practices or analysis of its offer that may assist you in your consideration of this company.
We know of no other matter or practice relating to this company that may assist you in your consideration of this company.
BCA has no information regarding advertising review at this time.
DBAs:There are no additional DBAs.
Websites:There are no additional web sites.
Contacts:There are no additional contacts.
Other Categories:
Photo Gallery
Login to BCA
Login to participate on the website. Write reviews, ask and respond to questions,
get quotes and more. Don't have an account?
Sign up for free now
Sign up with BCA
Sign up for free to participate on the website. Write reviews, ask and respond to questions,
get quotes and more. Already have an account?
Forgot Password
Type in the email address you registered with. If we can verify it in our system, an email will be sent to you with your password.


text:
Login with social networks:
You don't have account?
Ispuni kratki upitnik i osvoji jednu od tri vrijedne nagrade!
Popuni upitnikNe zanima me
This ad is not active. Ad application not possible.
This job ad is provided by PosLovac, mobile app for jobseekers.
Application deadline:
Care (children, elderly...)
Prosječna plaća u kategoriji Administration iznosi 819,77 EUR (6.176,54 kuna).
Saznaj plaću za željenu poziciju prema svojim kvalifikacijama!
Today, MojPosao is among top 20 most visited websites in Croatia, with more than 770.000 monthly visitors. So far, more than 54.000 clients started their recruitment process through MojPosao.
MojPosao is operated by Tau on – line Ltd. which is part of Alma Career.
MojPosao © 2000. - 2023.
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. Learn more.


text:
Want to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.
Home Industries Health Services CODAC, BH Link work together to address rise in opioid overdoses
Sign in
Welcome! Log into your account
Password recovery
Recover your password
A password will be e-mailed to you.


text:
Have no fear. HelloTech is here! We can send a tech to your door today or at your convenience to help with all your tech support needs. In many cases, we can solve your issues remotely by simply connecting to your computer. HelloTech also offers home and business tech support plans starting at $9.99. We serve Scotts Valley, California as well as the rest of the US.
We are Scotts Valley's choice for in-home tech support, computer services, installations & setups, and professional help with all your technology needs.
Booking your in-home service or online help is easy and takes just seconds. Choose when you want your service done and get a confirmed appointment time, not the 4-hour wait-around-window other professionals use. We have tech support and installation professionals near you, and they take care of the rest.
HelloTech's Scotts Valley geeks are experts, insured, and backed by HelloTech's Satisfaction Guarantee. So feel secure that your local technician will arrive on time, follow instructions, and perfectly complete your job.
We have TV mounting techs near you. We offer same-day TV mounting service backed by the HelloTech satisfaction guarantee. HelloTech experts are available 7 days a week to hang your TV perfectly and hide those ugly wires. Don't have a mounting bracket? We can bring one for you!
Tired of slow and spotty internet? Our expert techs know how to speed up slow internet. We'll fix your network connection, boost your WiFi signal, and give you the fastest internet possible. Does your WiFi keep dropping out? We will fix your WiFi, establishing a stable, secure connection. Having trouble with your devices? We will connect all of your mobile and smart devices to your WiFi network and make everything work seamlessly.
We'll connect your smart home to make sure all smart devices are working together. Trust the 5-star rated home automation service professionals. Installing products like smart doorbells, plugs, locks, alarms, switches, hubs, lights, thermostats and cameras. From brands like Nest, Arlo, Netgear, Skybell, Samsung, ecobee, Logitech, Iris, Google, Amazon, Ring, August, Honeywell and Sensi.
Need help connecting your TV and home theater? Let one of our Techs work their audio video magic. We'll hook up surround sound speakers, make sure you can stream videos, adjust any wiring, and make sure sound is functioning properly.
Need computer repair near you? HelloTech offers the highest quality computer repair service nationwide. Troubleshooting operating system, memory, RAM or hard drive issues. In-home or online help for your Mac or PC, on-demand.
In-home support for your mobile Apple or Android device when you need it. Help with your phone, tablet troubleshooting, and more. We'll diagnose and fix your mobile problem.


text:
(303) 841-6458
Parker, CO
We support the brave people of Ukraine in their fight to save their freedom and democracy
We support the brave people of Ukraine in their fight to save their freedom and democracy
Toggle navigation
About Us
Quick Quote
Personal Insurance
Auto Insurance
ATV Insurance
Boat Insurance
Classic Car Insurance
Condo Insurance
Earthquake Insurance
Flood Insurance
Home Insurance
Landlord Insurance
Life Insurance
Mobile Home Insurance
Motorcycle Insurance
RV Insurance
Renters Insurance
Short Term Rental Insurance
SR22 Insurance
Umbrella Insurance
Windstorm Insurance
Business Insurance
Business Owners Insurance
Business Auto Insurance
Builders Risk Insurance
Commercial General Liability
Commercial Auto
Commercial Property
Contractors Insurance
Cyber Liability Insurance
Farm Owners Insurance
Liquor Liability Insurance
Martial Arts Insurance
Restaurant Insurance
Special Event Insurance
Surety Bonds
Trucking Insurance
Workers Comp Insurance
Customer Service
Report a Claim
Make a Payment Online
Change of Address
Request a Certificate
Thank You
Thank you so much for contacting us! We will diligently work to respond to you as quickly as possible.
Insurance coverage cannot be bound or changed via submission of this online form. We will contact you to confirm changes to your policy
We strive to provide you with the best service possible. Please let us know if there is anything we can do to make your job easier by calling us at
or by replying to this email.
Have a wonderful day!
The Storie Insurance Agency
19501 Mainstreet, Suite 200, Parker, CO 80138
© 2009-2023
Websites by Agency Relevance
, All Rights Reserved.


text:
What's going on with your Galaxy S8 Active? Select all that apply. If you're not sure, select what you think it may be. You'll never pay for a repair that doesn't solve the problem!
A cracked or shattered screen is by far the most common issue we see on most phones. Don't cut your fingers and stop walking around with a shattered piece of glass in your pocket. We have repaired hundreds of Galaxy S8 Active screens and can fix yours too. We use high quality parts and a proven repair process all backed by our superb warranty.
Batteries break down over time and hold less of a charge. If you have to plug your Galaxy S8 Active in frequently or the battery doesn't seem to be as good as it used to, it may be time to have it replaced. We can replace your Galaxy S8 Active's battery and have it working as good as it did when it was new!
Very few things are more frustrating than a broken charge dock on your Galaxy S8 Active. If your Galaxy S8 Active will not charge, the charging cable refuses to properly connect, or the connection is loose, this service is for you.
The front camera, commonly called the "Selfie" camera, can stop working properly for many reasons. Sometimes it's blurry and other times the front camera simply won't load. Regardless of the cause, if the front camera on your Galaxy S8 Active isn't working the way it should be, we can fix that right up!
Similar to the power button, the volume buttons on your Galaxy S8 Active may be mechanical and prone to wear or breakage. If your volume up, volume down, or mute buttons aren't working select this service and we'll restore your Galaxy S8 Active's full abilities.
As one of the few remaining mechanical parts on your Galaxy S8 Active, the power button may stop working over time. Dirt or liquid may make its way inside the gaskets underneath the button and cause it to stop working. Book this service if your Galaxy S8 Active is having issues with it's power button.
If your friends and family have trouble hearing you in phone calls it's probably not your fault. Microphones can get dirty and become quiet over time. In some cases, they may even stop working completely! If you believe the microphone on your Galaxy S8 Active isn't operating the way it should, book this service and we'll take care of it.
Water and other liquids can make their way inside your Galaxy S8 Active even without it becoming fully submerged. Water-resistant and water-proof phones are still at risk of becoming liquid damaged under certain circumstances. Water damage repair can range from a simple replacement of the affected components all the way to a complete teardown of your Galaxy S8 Active and micro-solder repairs on the motherboard. We specialize in treating water damaged Galaxy S8 Actives and are highly experienced in motherboard repair.
If your Galaxy S8 Active is acting weird or you're having trouble determining exactly what's causing an unusual issue, let us figure it out for you. Our diagnostic service is free for the first hour which, in almost all cases, provides more than enough time for us to diagnose the root cause of whatever issues your Galaxy S8 Active may have.


text:
Multiplying Fractions
I show how to solve math problems online during live instruction in class. This is my way of providing free tutoring for the students in my class and for students anywhere in the world. Every video is a short clip that shows exactly how to solve math problems step by step. The problems are done in real time and in front of a regular classroom. These videos are intended to help you learn how to solve math problems, review how to solve a math problems, study for a test, or finish your homework. I post all of my videos on YouTube, but if you are looking for other ways to interact with me and my videos you can follow me on the following pages through My Blog, Twitter, or Facebook.


text:
Export 3 results:Author [ Title] Type Year
Filters: Author is Jon Ove Hagen [Clear All Filters]
"Mountain Glaciers and ice caps", Arctic Monitoring and Assessment Programme (AMAP), Oslo, Norway, xii, 2012.,
"A Reconciled Estimate of Glacier Contributions to Sea Level Rise: 2003 to 2009", Science, vol. 340, pp. 852-857, 2013.,
"The role of subsurface heat exchange: energy partitioning at Austfonna ice cap, Svalbard, over 2004-2008", Annals of Glaciology, vol. 54, no. 63, pp. 229-240, 2013.,


text:
Sierra Club Radio - April 14, 2012
This week on Sierra Club Radio:
« Sierra Club Radio - April 7, 2012 | Main | Sierra Club Radio - April 21, 2012 »
This week on Sierra Club Radio:
TrackBack URL for this entry:
Listed below are links to weblogs that reference Sierra Club Radio - April 14, 2012:
The comments to this entry are closed.
With Your Host: Orli Cotel
Contact Sierra Club Radio
The Green Life:
Ideas for Living Well and Doing Good
User comments or postings reflect the opinions of the responsible contributor only, and do not reflect the viewpoint of the Sierra Club. The Sierra Club does not endorse or guarantee the accuracy of any posting. The Sierra Club accepts no obligation to review every posting, but reserves the right (but not the obligation) to delete postings that may be considered offensive, illegal or inappropriate.


text:
Presto Standard series color gels in new convenient smaller size (2.7g) at great lower price. Sheer finish. High-quality, professional color gel specially tested for ease-of-use. Even, brilliant coloration for a beautiful finish. No mixing or shaking necessary. Brush sold separately.
Both LED and UV light curable; recommended to cure with Presto LED light for the best cure.
Curing time : Presto LED Light - 20sec, UV Light (36W) - 120sec
Size: 2.7g
Made in Japan. Store in a cool, dark place away from any direct light sources for longevity.
Finish: Sheer
- Colors may differ from actual product depending on each individual screen setting
- Suggested curing time is for Presto LED light only. Other LED lights may require different curing times.
- Please utilize the product within 3 years after purchasing and use within 1 year after opening the product.
- Product quality can change with light and heat exposure so it is recommended that all products are stored in a dark cool place
- Soft Gel/Soak Off Gel


text:
Office Depot Brand 2 Mil Reclosable Poly Bags, 13in x 13in, Clear, Case Of 1000
Mfg Name: B O X MANAGEMENT, INC.
Mfg Number: PB3613
Type: Mailing, Packing & Shipping
Weight: 1 LB
Green Item: No
Unit Count: 1000
Country of Origin: CN
UNSPSC Code: 24121502
Single track zipper extends the width of the bag and keeps products clean and free from moisture. Reclosable bags can be reused. Bags meet FDA and USDA requirements. Sizes listed are the inside usable dimensions of the bag.
Shipping Policy
We have a 30-day return policy, which means you have 30 days after receiving your item to request a return. To be eligible for a return, your item must be in the same condition that you received it, unworn or unused, with tags, and in its original packaging. You'll also need the receipt or proof of purchase.
To start a return, you can contact us at email@example.com. If your return is accepted, we'll send you a return shipping label, as well as instructions on how and where to send your package. Items sent back to us without first requesting a return will not be accepted.You can always contact us for any return question at email@example.com.
Damage and Issues
Please inspect your order upon reception and contact us immediately if the item is defective, damaged or if you receive the wrong item, so that we can evaluate the issue and make it right.
We will notify you once we've received and inspected your return, and let you know if the refund was approved or not. If approved, you'll be automatically refunded on your original payment method. Please remember it can take some time for your bank or credit card company to process and post the refund too.
Certain types of items cannot be returned, like perishable goods (example: food, flowers, or plants), custom products (such as special orders or personalized items), and personal care goods (such as beauty products). We also do not accept returns for hazardous materials, flammable liquids, or gases. Please get in touch if you have questions or concerns about your specific item..
The fastest way to ensure you get what you want is to return the item you have, and once the return is accepted, make a separate purchase for the new item.
To save your time and reach our support quickly, please either reach out to us via our chat tool and we will respond as soon as possible. You can always contact us for any return question at email@example.com.


text:
Discover Tidelands Health Get Care Now
I am looking for...
Discover Tidelands Health
Get Care Now
The National Women's Health Information Center offers the following 10 things you can do to help live longer, live better, and live happier:
Be informed. Learn about health promotion and disease prevention and ask your healthcare provider for specific information regarding your needs.
Be good to your bones. For healthy bones, be sure to replenish your stock of calcium every day with plenty of foods such as milk and other dairy products, tofu, leafy green vegetables, canned salmon or sardines, and calcium-fortified juices or breads. Speak with your healthcare provider about calcium supplements.
Don't use illegal drugs and limit alcohol. For women, the definition of moderate drinking stops at one drink a day. The National Institute on Alcohol Abuse and Alcoholism defines a drink as one 5-ounce glass of wine, one 12-ounce bottle of beer or wine cooler, or 1.5 ounces of 80-proof distilled spirits. Remember that the alcohol content of each type of drink can vary widely. Where illicit drugs are concerned, there is no such thing as "safe" or "moderate" use.
Take medicine wisely. Read the labels, follow the instructions carefully, and remind your healthcare provider or pharmacist about any other medicines or supplements you might be taking that could interact with your medicines. For your safety – to lower your risk for adverse side effects or medicine interactions, you should also let your healthcare provider know if you use any illicit or "recreational" drugs. If you have any questions about possible side effects, call your healthcare provider or pharmacist.
Play it safe. Avoid injuries. Buckle up. Wear motorcycle and bicycle helmets. Use smoke and carbon monoxide detectors. Wear sunscreen and UV protected sunglasses. Use street smarts and common sense. Practice safe sex by using condoms to protect against sexually transmitted infections.
Get checked. Get regular checkups, preventive exams, and immunizations. Don't forget self-exams, too. These include skin, oral, and breast self-checks.
Don't smoke. Smoking is the leading preventable cause of death in our country.
Eat smart. It is the secret to good health. Eat plenty of fruits, vegetables, and whole grains. Enjoy a variety of foods, balance foods from each food group, and exercise in moderation.
Get moving. The other secret to good health: just 30 minutes of physical activity, accumulated over the course of each day, can radically improve the way you look and feel, both physically and mentally.
Be happy. Take time for yourself. Get connected with family, friends, and community. Do things you enjoy!
This chart provides general healthcare guidelines for women, but is not meant to replace any advice and guidance given by your healthcare provider. Please use it as a reminder to take care of your personal healthcare needs, and also as a list of topics you may want to discuss with your healthcare provider.
Each day
Each month
Each year
Exercise 30 minutes a day.
Do an oral cavity self-exam, gums, teeth, lips, tongue
Have a dental checkup once or twice a year. Have vision and hearing checked annually.
Discuss with your healthcare provider whether you need an annual exam.
Protect yourself from the sun - use sunscreen and dress appropriately.
Do a full-body self-exam for unusual moles or other skin conditions. Have your healthcare provider examine moles annually, or immediately for suspicious growths.
Have a pelvic exam and Pap test starting at age 21.Talk with your healthcare provider about his or her recommendations for further testing and screening for the human papillomavirus, or HPV.*
After age 50:
Have a fecal occult blood test every year, or have a flexible sigmoidoscopy every 5 years, OR
Have a double contrast barium enema every 5 years, OR
Have a colonoscopy every 10 years
Start screening with a colonoscopy at age 45 in African Americans
Watch your fat intake - no more than 25 % to 35% of your calorie intake. Most fats should come from sources of polyunsaturated and monounsaturated fatty acids, such as fish, nuts, and vegetable oils.
Be aware of your weight, check your BMI (body mass index)
Have your blood pressure and cholesterol levels checked
Starting at age 45: every 5 years have a full lipid profile test for cholesterol and triglycerides.
Earlier screening is recommended if you have risk factors for coronary artery disease.
Eat sources of protein such as lean or low-fat meat, poultry, fish, dry beans, eggs, and nuts.
Eat 5 to 9 services of fruits and vegetables daily.
At least half of all of the grains eaten should be whole-grains.
Consume 3 cups of fat-free or low-fat milk or equivalent milk products per day.
Talk with your doctor about when you should have a mammogram.
Get pneumococcal and shingles vaccines. Ask your healthcare provider if any other vaccinations are needed or if immunization recommendations have changed.
After age 65: get the pneumococcal vaccines; also recommended for those younger than 65 who have medical problems that increase the risk for serious complications and death
Be aware of your alcohol intake and stress level.
Get a flu shot.
Get a tetanus/diphtheria (td) booster every 10 years
* The American Congress of Obstetricians and Gynecologists recommends that women have their first Pap test at age 21. Women ages 21 to 29 should have a Pap test every 3 years. Women 30 and older are recommended to have co-testing with cytology and HPV every 5 years, or cytology every 3 years. It's reasonable to discontinue screening for cervical cancer in women age 65 and over after receiving negative prior screening tests if there is no history of cervical intraepithelial neoplasia (CIN) 2+ within the last 20 years. After screening has been discontinued, it should not be resumed, even if a woman has multiple sexual partners.


text:
Shot in the Park
Sacramento News & Review | September 2, 2015
Sacramento News & Review
Innovative and intelligent, Sacramento's favorite weekly publication has long been the Sacramento News & Review. In fact, the News & Review is Sacramento's second-largest newspaper, so its readers are as diverse as Sacramento itself. With irreverence and attitude, the News...More »
Contact for Reprint Rights
- Market Served: Metropolitan Area
- Address: 1124 Del Paso Blvd., Sacramento, CA 95815
- Phone: (916) 498-1234


text:
National Institutes of Health (NIH)
National Institute on Aging (NIA)
Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)
Reissue of PAS-17-065
PAS-18-187, SBIR R43/R44- Phase I, Phase II, and Fast Track
This Funding Opportunity Announcement (FOA) encourages applications to NIA's Small Business Technology Transfer Research (STTR)program to conduct research leading to the development of innovative products and/or services that may advance progress in preventing and treating Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD) and/or caring for and treating AD/ADRD patients.
November 28, 2017
March 6, 2018
30 days prior to the application due date
Standard dates apply, by 5:00 PM local time of applicant organization.
*** Note new SBIR/STTR Standard Due Dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Not Applicable
New Date July 17 , 2019 per issuance of PAS-19-317. (Original Expiration Date: September 6, 2019)
Not Applicable
It is critical that applicants follow the SBIR/STTR (B) Instructions in the SF424 (R&R) SBIR/STTR Application Guide except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.
Part 1. Overview Information
Part 2. Full Text of the Announcement
I. Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission Information
Section V. Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information
In the United States (US), it is estimated that more than 5 million people suffer from Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD). By 2050 this number is forecast to rise to more than 15 million. Moreover, caring for and treating patients with AD/ADRD is expensive. Current estimated annual costs for care and treatment of AD/ADRD total approximately $200 billion.
Recent recommendations and milestones for AD/ADRD research from the National Alzheimer's Project Act, the 2012 Alzheimer's Disease Research Summit, the 2013 Alzheimer's Disease and Related Dementias Meeting, and the 2015 Alzheimer's Disease Research Summit present a wide range of research and development, which , if conducted, is expected to reduce the human burden and health-care costs associated with AD and ADRD.
As part of the National Institute on Aging's (NIA) strategic plan to support the development of innovative strategies and therapies to prevent, diagnose, and treat AD/ADRD, NIA announces a new Funding Opportunity Announcement (FOA) through its Small Business Technology Transfer Research Program (STTR) to encourage research on and the commercialization of novel therapies, devices, other products, and health care programs and practices to prevent the onset of AD/ADRD and to reduce their burden on individuals, their families, and society at large.
STTR is an important small business program that expands funding opportunities in the federal innovation research and development arena. Central to the program is expansion of the public/private sector partnership to include the joint venture opportunities for small business and the nation's premier nonprofit research institutions. STTR's most important role is to foster the innovation necessary to meet the nation's scientific and technological challenges in the 21st century.
Examples of research and development that might be supported by this FOA include but are not limited to:
See Section VIII. Other Information for award authorities and regulations.
Grant: A support mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.
New (Phase I, Fast-Track)
Renewal (Phase II* Direct Phase II not allowed)
Resubmission (all phases)
Phase IIB Competing Renewal (Phase IIB)
The OER Glossary and the SF424 (R&R) SBIR/STTR Application Guide provide details on these application types.
Optional: Accepting applications that either propose or do not propose clinical trial(s)
Need help determining whether you are doing a clinical trial?
NIA intends to commit $5 Million in FY 2017 to fund 10 awards.
According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics. The current list of approved topics can be found at https://sbir.nih.gov/funding#omni-sbir. Applicants are strongly encouraged to contact NIH program officials prior to submitting any application in excess of the guidelines and early in the application planning process. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project.
Phase IIB budgets must be submitted in accordance with participating IC-specific budget limitations described in the current SBIR/STTR Program Descriptions and Research Topics of the NIH, CDC and FDA.
According to statutory guidelines, award periods normally may not exceed 1 year for Phase I and 2 years for Phase II. Applicants are encouraged to propose a project duration period that is reasonable and appropriate for completion of the research project.
NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made in response to this FOA.
Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity. A small business concern is one that, at the time of award of Phase I and Phase II, meets all of the following criteria:
1. Is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor;
2. Is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture;
i. SBIR and STTR. Be a concern which is more than 50% directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50% directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these; OR
ii. SBIR-only. Be a concern which is more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50% of the concern; OR
iii. SBIR and STTR. Be a joint venture in which each entity to the joint venture must meet the requirements set forth in paragraph 3 (i) or 3 (ii) of this section. A joint venture that includes one or more concerns that meet the requirements of paragraph (ii) of this section must comply with § 121.705(b) concerning registration and proposal requirements.
4. Has, including its affiliates, not more than 500 employees.
If the concern is more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these falls under 3 (ii) or 3 (iii) above, see Section IV. Application and Submission Information for additional instructions regarding required application certification.
If an Employee Stock Ownership Plan owns all or part of the concern, each stock trustee and plan member is considered an owner.
If a trust owns all or part of the concern, each trustee and trust beneficiary is considered an owner.
SBCs must also meet the other regulatory requirements found in 13 C.F.R. Part 121. Business concerns, other than investment companies licensed, or state development companies qualifying under the Small Business Investment Act of 1958, 15 U.S.C. 661, et seq., are affiliates of one another when either directly or indirectly, (a) one concern controls or has the power to control the other; or (b) a third-party/parties controls or has the power to control both. Business concerns include, but are not limited to, any individual (sole proprietorship) partnership, corporation, joint venture, association, or cooperative. The SF424 (R&R) SBIR/STTR Application Guide should be referenced for detailed eligibility information.
Small business concerns that are more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these are NOT eligible to apply to the NIH STTR program.
Phase I to Phase II Transition Rate Benchmark
In accordance with guidance from the SBA, the HHS SBIR/STTR Program is implementing the Phase I to Phase II Transition Rate benchmark required by the SBIR/STTR Reauthorization Act of 2011. This Transition Rate requirement applies to SBIR and STTR Phase I applicants that have received more than 20 Phase I awards over the past 5 fiscal years, excluding the most recently-completed fiscal year. For these companies, the benchmark establishes a minimum number of Phase II awards the company must have received for a given number of Phase I awards received during the 5-year time period in order to be eligible to receive a new Phase I award. This requirement does not apply to companies that have received 20 or fewer Phase I awards over the 5 year period.
Companies that apply for a Phase I award and do not meet or exceed the benchmark rate will not be eligible for a Phase I award for a period of one year from the date of the application submission. The Transition Rate is calculated as the total number of SBIR and STTR Phase II awards a company received during the past 5 fiscal years divided by the total number of SBIR and STTR Phase I awards it received during the past 5 fiscal years excluding the most recently-completed year. The benchmark minimum Transition Rate is 0.25.
SBA calculates individual company Phase I to Phase II Transition Rates daily using SBIR and STTR award information across all federal agencies. For those companies that have received more than 20 Phase I awards over the past 5 years, SBA posts the company transition rates on the Company Registry at SBIR.gov. Information on the Phase I to Phase II Transition Rate requirement is available at SBIR.gov.
Applicants to this FOA that may have received more than 20 Phase I awards across all federal SBIR/STTR agencies over the past five (5) years should, prior to application preparation, verify that their company's Transition Rate on the Company Registry at SBIR.gov meets or exceeds the minimum benchmark rate of 0.25.
Phase II to Phase III Commercialization Benchmark
In accordance with guidance from the SBA, HHS, including NIH, SBIR/STTR Programs are implementing the Phase II to Phase III Commercialization Rate benchmark for Phase I applicants, as required by the SBIR/STTR Reauthorization Act of 2011. The Commercialization Rate Benchmark was published in a Federal Register notice on August 8, 2013 (78 FR 48537).
This requirement applies to companies that have received more than 15 Phase II awards from all agencies over the past 10 years, excluding the two most recently-completed Fiscal Years. Companies that meet this criterion must show an average of at least $100,000 in revenues and/or investments per Phase II award or at least 0.15 (15%) patents per Phase II award resulting from these awards. This requirement does not apply to companies that have received 15 or fewer Phase II awards over the 10 year period, excluding the two most recently-completed Fiscal Years.
Information on the Phase II to Phase III Commercialization Benchmark is available at SBIR.gov.
Applicants to this FOA that may have received more than 15 Phase II awards across all federal SBIR/STTR agencies over the past ten (10) years should, prior to application preparation, verify that their company's Commercialization Benchmark on the Company Registry at SBIR.gov meets or exceeds the benchmark rate listed above.
Applicants that fail this benchmark will be notified by SBA annually and will not be eligible to receive New Phase I, Fast-track or Direct Phase II awards for a period of one year.
Non-domestic (non-U.S.) Entities (Foreign Institutions) are
not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Applicant Organizations
Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.
Program Directors/Principal Investigators (PD(s)/PI(s))
All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.
Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.
For the STTR program, the PD(s)/PI(s) may be employed with the SBC or the single, "partnering" non-profit research institution as long as s/he has a formal appointment with or commitment to the applicant SBC, which is characterized by an official relationship between the SBC and that individual. Each PD/PI must commit a minimum of 10% effort to the project and the PD/PI must have a formal appointment with or commitment to the applicant small business concern, which is characterized by an official relationship between the small business concern and that individual. Such a relationship does not necessarily involve a salary or other form of remuneration.
The SF424 (R&R) SBIR/STTR Application Guide should be referenced for specific details on eligibility requirements. For institutions/organizations proposing multiple PDs/PIs, see Multiple Principal Investigators section of the SF424 (R&R) SBIR/STTR Application Guide.
This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.
Applicant organizations may submit more than one application, provided that each application is scientifically distinct.
NIH will not accept similar grant applications with essentially the same research focus from the same applicant organization. This includes derivative or multiple applications that propose to develop a single product, process, or service that, with non-substantive modifications, can be applied to a variety of purposes. Applicants may not simultaneously submit identical/essentially identical applications under both this funding opportunity and any other HHS funding opportunity, including the SBIR and STTR Parent announcements.
The NIH will not accept duplicate or highly overlapping applications under review at the same time. This means that the NIH will not accept:
A Phase I awardee may submit a Phase II application either before or after expiration of the Phase I budget period, unless the awardee elects to submit a Phase I and Phase II application concurrently under the Fast-Track procedure. To maintain eligibility to seek Phase II or IIB support, a Phase I awardee should submit a Phase II application, and a Phase II awardee should submit a Phase IIB application, within the first six due dates following the expiration of the Phase I or II budget period, respectively.
In Phase I and Phase II, at least 40% of the research or analytical effort must be performed by the small business concern and at least 30% of the research or analytical effort must be performed by the single, "partnering" research institution. The basis for determining the percentage of work to be performed by each of the cooperative parties will be the total of direct and F&A/indirect costs attributable to each party, unless otherwise described and justified in "Consortium/Contractual Arrangements" of the PHS 398 Research Plan component of the SF424 (R&R) application forms.
A small business concern may subcontract a portion of its SBIR or STTR award to a Federal laboratory within the limits above. A Federal laboratory, as defined in 15 U.S.C. § 3703, means any laboratory, any federally funded research and development center, or any center established under 15 U.S.C. §§ 3705 & 3707 that is owned, leased, or otherwise used by a Federal agency and funded by the Federal Government, whether operated by the Government or by a contractor.
The basis for determining the percentage of work to be performed by each of the cooperative parties in Phase I or Phase II will be the total of the requested costs attributable to each party, unless otherwise described and justified in "Consortium/Contractual Arrangements" of the PHS 398 Research Plan component of SF424 (R&R) application forms.
Additional details are contained in the SF424 (R&R) SBIR/STTR Application Guide.
Buttons to access the online ASSIST system or to download application forms are available in Part 1 of this FOA. See your administrative office for instructions if you plan to use an institutional system-to-system solution.
It is critical that applicants follow the SBIR/STTR (B) Instructions in the SF424 (R&R) SBIR/STTR Application Guide, including Supplemental Grant Application Instructions except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
For information on Application Submission and Receipt, visit Frequently Asked Questions – Application Guide, Electronic Submission of Grant Applications.
All page limitations described in the SF424 (R&R) SBIR/STTR Application Guide and the Table of Page Limits must be followed.
Instructions for Application Submission
The following section supplements the instructions found in the SF 424 (R&R) SBIR/STTR Application Guide and should be used for preparing an application to this FOA.
All instructions in the SF424 (R&R) SBIR/STTR Application Guide must be followed.
All instructions in the SF424 (R&R) SBIR/STTR Application Guide must be followed.
All instructions in the SF424 (R&R) SBIR/STTR Application Guide must be followed, with the following additional instructions:
Other Attachments:
1. SBA Company registry
All applicants to the SBIR and STTR programs are required to register at the SBA Company Registry prior to application submission and attach proof of registration. Completed registrations will receive a unique SBC Control ID and .pdf file. If applicants have previously registered, you are still required to attach proof of registration. The SBA Company Registry recommends verification with SAM, but a SAM account is not required to complete the registration. In order to be verified with SAM, your email address must match one of the contacts in SAM. If you are unsure what is listed in SAM for your company, you may verify the information on the SAM site. Confirmation of your company's DUNS is necessary to verify your email address in SAM. Follow these steps listed below to register and attach proof of registration to your application.
a. Navigate to the SBA Company Registry.
b. If you are a previous SBIR/STTR awardee from any agency, search for your small business by Company Name, EIN/Tax ID, DUNS, or Existing SBIR/STTR Contract/Grant Number in the search fields provided. Identify your company and click "Proceed to Registration".
c. If you are a first time applicant, click the "New to the SBIR Program?" link on lower right of registry screen.
d. Fill out the required information on the "Basic Information" and "Eligibility Statement" screens.
e. Press "Complete Registration" on the lower right of the "Eligibility Statement" screen and follow all instructions.
f. Download and save your SBA registry PDF locally. The name will be in the format of SBC_123456789.pdf, where SBC_123456789 (9 digit number) is your firm's SBC Control ID. DO NOT CHANGE OR ALTER THE FILE NAME. Changing the file name may cause delays in the processing of your application.
g. When you are completing the application package, attach this SBA registry PDF as a separate file by clicking "Add Attachments" located to the right of the Other Attachments field on the "Research and Related Other Project Information" form.
For questions and for technical assistance concerning the SBA Company Registry, please contact the SBA at http://sbir.gov/feedback?type=reg.
All instructions in the SF424 (R&R) SBIR/STTR Application Guide must be followed.
All instructions in the SF424 (R&R) SBIR/STTR Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) SBIR/STTR Application Guide must be followed.
All instructions in the SF424 (R&R) SBIR/STTR Application Guide must be followed, with the following additional instructions:
Resource Sharing Plans: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) SBIR/STTR Application Guide.
Appendix: Do not use the Appendix to circumvent page limits. The instructions for the Appendix of the Research Plan are described in the SF424 (R&R) Application Guide.
Note that Phase I SBIR/STTR Appendix materials are not permitted.
When involving NIH-defined human subjects research, clinical research, and/or clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:
If you answered "Yes" to the question "Are Human Subjects Involved?" on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a delayed onset study record.
Study Record: PHS Human Subjects and Clinical Trials Information: All instructions in the SF424 (R&R) Application Guide must be followed.
Delayed Onset Study: All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) SBIR/STTR Application Guide must be followed.
See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), SBA Company Registry, eRA Commons, and Grants.gov.
Part I. Overview Information contains information about Key Dates and time. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.
Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH's electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Policy on Late Application Submission.
Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.
Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) SBIR/STTR Application Guide.
This initiative is not subject to intergovernmental review.
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Pre-award costs are allowable only as described in the NIH Grants Policy Statement.
Applications must be submitted electronically following the instructions described in the SF424 (R&R) SBIR/STTR Application Instructions. Paper applications will not be accepted.
Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.
For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Guidelines for Applicants Experiencing System Issues. For assistance with application submission, contact the Application Submission Contacts in Section VII.
Important reminders:
All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH.
The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization's profile in the eRA Commons and for the System for Award Management (SAM). Additional information may be found in the SF424 (R&R) SBIR/STTR Application Guide.
See more tips for avoiding common errors.
Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review, NIH. Applications that are incomplete or non-compliant will not be reviewed.
Applicants are required to follow the instructions for post-submission materials, as described in the policy.
Important Update: See NOT-OD-18-228 for updated review language for due dates on or after January 25, 2019.
Only the review criteria described below will be considered in the review process. As part of the NIH mission, all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.
Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).
For this particular announcement, note the following: A proposed Clinical Trial application may include study design, methods, and intervention that are not by themselves innovative but address important questions or unmet needs. Additionally, the results of the clinical trial may indicate that further clinical development of the intervention is unwarranted or lead to new avenues of scientific investigation.
Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.
Does the project address an important problem or a critical barrier to progress in the field? Is there a strong scientific premise for the project? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field? Does the proposed project have commercial potential to lead to a marketable product, process or service? (In the case of Phase II, Fast-Track, and Phase II Competing Renewals, does the Commercialization Plan demonstrate a high probability of commercialization?)
In addition, for applications proposing clinical trials: Are the scientific rationale and need for a clinical trial to test the proposed hypothesis or intervention well supported by preliminary data, clinical and/or preclinical studies, or information in the literature or knowledge of biological mechanisms? For trials focusing on clinical or public health endpoints, is this clinical trial necessary for testing the safety, efficacy or effectiveness of an intervention that could lead to a change in clinical practice, community behaviors or health care policy? For trials focusing on mechanistic, behavioral, physiological, biochemical, or other biomedical endpoints, is the trial needed to advance scientific understanding?
Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?
In addition, for applications proposing clinical trials: With regard to the proposed leadership for the project, do the PD/PI(s) and key personnel have the expertise, experience, and ability to organize, manage and implement the proposed clinical trial and meet milestones and timelines? Do they have appropriate expertise in study coordination, data management and statistics? For a multicenter trial, is the organizational structure appropriate and does the application identify a core of potential center investigators and staffing for a coordinating center?
Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?
In addition, for applications proposing clinical trials: Does the design/research plan include innovative elements, as appropriate, that enhance its sensitivity, potential for information or potential to advance scientific knowledge or clinical practice?
Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?
If the project involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of children, justified in terms of the scientific goals and research strategy proposed?
In addition, for applications proposing clinical trials: Does the application adequately address the following, if applicable:
Is the study design justified and appropriate to address primary and secondary outcome variable(s)/endpoints that will be clear, informative and relevant to the hypothesis being tested? Is the scientific rationale/premise of the study based on previously well-designed preclinical and/or clinical research? Given the methods used to assign participants and deliver interventions, is the study design adequately powered to answer the research question(s), test the proposed hypothesis/hypotheses, and provide interpretable results? Is the trial appropriately designed to conduct the research efficiently? Are the study populations (size, gender, age, demographic group), proposed intervention arms/dose, and duration of the trial, appropriate and well justified?
Are potential ethical issues adequately addressed? Is the process for obtaining informed consent or assent appropriate? Is the eligible population available? Are the plans for recruitment outreach, enrollment, retention, handling dropouts, missed visits, and losses to follow-up appropriate to ensure robust data collection? Are the planned recruitment timelines feasible and is the plan to monitor accrual adequate? Has the need for randomization (or not), masking (if appropriate), controls, and inclusion/exclusion criteria been addressed? Are differences addressed, if applicable, in the intervention effect due to sex/gender and race/ethnicity?
Are the plans to standardize, assure quality of, and monitor adherence to, the trial protocol and data collection or distribution guidelines appropriate? Is there a plan to obtain required study agent(s)? Does the application propose to use existing available resources, as applicable?
Are planned analyses and statistical approach appropriate for the proposed study design and methods used to assign participants and deliver interventions? Are the procedures for data management and quality control of data adequate at clinical site(s) or at center laboratories, as applicable? Have the methods for standardization of procedures for data management to assess the effect of the intervention and quality control been addressed? Is there a plan to complete data analysis within the proposed period of the award?
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangement?
In addition, for applications proposing clinical trials: If proposed, are the administrative, data coordinating, enrollment and laboratory/testing centers, appropriate for the trial proposed? Does the application adequately address the capability and ability to conduct the trial at the proposed site(s) or centers? Are the plans to add or drop enrollment centers, as needed, appropriate? If international site(s) is/are proposed, does the application adequately address the complexity of executing the clinical trial? If multi-sites/centers, is there evidence of the ability of the individual site or center to: (1) enroll the proposed numbers; (2) adhere to the protocol; (3) collect and transmit data in an accurate and timely fashion; and, (4) operate within the proposed organizational structure?
As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.
For Phase II Applications, how well did the applicant demonstrate progress toward meeting the Phase I objectives, demonstrating feasibility, and providing a solid foundation for the proposed Phase II activity?
For Phase I/Phase II Fast-Track Applications, reviewers will consider the following:
1. Does the Phase I application specify clear, appropriate, measurable goals (milestones) that should be achieved prior to initiating Phase II?
2. To what extent was the applicant able to obtain letters of interest, additional funding commitments, and/or resources from the private sector or non-SBIR/STTR funding sources that would enhance the likelihood for commercialization?
For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.
When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of children to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.
The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.
Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.
For Phase IIB Applications, the committee will consider the progress made in the last funding period.
Not Applicable
As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.
Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: (1) Data Sharing Plan; (2) Sharing Model Organisms; and (3) Genomic Data Sharing Plan.
For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.
Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by the Center for Scientific Review (CSR), in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.
As part of the scientific peer review, all applications:
Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this FOA. Following initial peer review, recommended applications will receive a second level of review by the National Advisory Council on Aging. The following will be considered in making funding decisions:
After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons. Refer to Part 1 for dates for peer review, advisory council review, and earliest start date
Information regarding the disposition of applications is available in the NIH Grants Policy Statement.
If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the NIH Grants Policy Statement.
A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee's business official.
Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.
Any application awarded in response to this FOA will be subject to terms and conditions found on the Award Conditions and Information for NIH Grants website. This includes any recent legislation and policy applicable to awards that is highlighted on this website.
Additionally, ICs may specify any special reporting requirements for the proposed clinical trial to be included under IC-specific terms and conditions in the NoA. For example: If the proposed clinical trial has elevated risks, ICs may require closer programmatic monitoring and it may be necessary to require the awardee to provide more frequent information and data as a term of the award (e.g., to clarify issues, address and evaluate concerns, provide documentation). All additional communications and information related to programmatic monitoring must be documented and incorporated into the official project file. Individual awards are based on the application submitted to, and as approved by, the NIH and are subject to the IC-specific terms and conditions identified in the NoA.
ClinicalTrials.gov: If an award provides for one or more clinical trials by law (Title VIII, Section 801 of Public Law 110-85), the "responsible party" must register and submit results information for certain "applicable clinical trials" on the ClinicalTrials.gov Protocol Registration and Results System Information Website (https://register.clinicaltrials.gov). NIH expects registration of all trials whether required under the law or not. For more information, see http://grants.nig.gov/ClinicalTrials_fdaaa/.
Institutional Review Board or Independent Ethics Committee Approval: Grantee institutions must ensure that the application as well as all protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the awardee must provide NIH copies of documents related to all major changes in the status of ongoing protocols.
Data and Safety Monitoring Requirements: The NIH policy for data and safety monitoring requires oversight and monitoring of all NIH-conducted or -supported human biomedical and behavioral intervention studies (clinical trials) to ensure the safety of participants and the validity and integrity of the data. Further information concerning these requirements is found at http://grants.nih.gov/grants/policy/hs/data_safety.htm and in the application instructions (SF424 (R&R) and PHS 398).
Investigational New Drug or Investigational Device Exemption Requirements: Consistent with federal regulations, clinical research projects involving the use of investigational therapeutics, vaccines, or other medical interventions (including licensed products and devices for a purpose other than that for which they were licensed) in humans under a research protocol must be performed under a Food and Drug Administration (FDA) investigational new drug (IND) or investigational device exemption (IDE).
All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.
Recipients of federal financial assistance (FFA) from HHS must administer their programs in compliance with federal civil rights law. This means that recipients of HHS funds must ensure equal access to their programs without regard to a person's race, color, national origin, disability, age and, in some circumstances, sex and religion. This includes ensuring your programs are accessible to persons with limited English proficiency. HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator's scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research.
For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this FOA. HHS provides general guidance to recipients of FFA on meeting their legal obligation to take reasonable steps to provide meaningful access to their programs by persons with limited English proficiency. Please see https://www.hhs.gov/civil-rights/for-individuals/special-topics/limited-english-proficiency/index.html. The HHS Office for Civil Rights also provides guidance on complying with civil rights laws enforced by HHS. Please see http://www.hhs.gov/ocr/civilrights/understanding/section1557/index.html; and https://www.hhs.gov/civil-rights/for-providers/laws-regulations-guidance/index.html. Recipients of FFA also have specific legal obligations for serving qualified individuals with disabilities. Please see http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html. Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at https://www.hhs.gov/ocr/about-us/contact-us/index.html or call 1-800-368-1019 or TDD 1-800-537-7697. Also note it is an HHS Departmental goal to ensure access to quality, culturally competent care, including long-term services and supports, for vulnerable populations. For further guidance on providing culturally and linguistically appropriate services, recipients should review the National Standards for Culturally and Linguistically Appropriate Services in Health and Health Care at http://minorityhealth.hhs.gov/omh/browse.aspx?lvl=2&lvlid=53.
In accordance with the statutory provisions contained in Section 872 of the Duncan Hunter National Defense Authorization Act of Fiscal Year 2009 (Public Law 110-417), NIH awards will be subject to the Federal Awardee Performance and Integrity Information System (FAPIIS) requirements. FAPIIS requires Federal award making officials to review and consider information about an applicant in the designated integrity and performance system (currently FAPIIS) prior to making an award. An applicant, at its option, may review information in the designated integrity and performance systems accessible through FAPIIS and comment on any information about itself that a Federal agency previously entered and is currently in FAPIIS. The Federal awarding agency will consider any comments by the applicant, in addition to other information in FAPIIS, in making a judgement about the applicant's integrity, business ethics, and record of performance under Federal awards when completing the review of risk posed by applicants as described in 45 CFR Part 75.205 "Federal awarding agency review of risk posed by applicants." This provision will apply to all NIH grants and cooperative agreements except fellowships.
The Office of Inspector General Hotline accepts tips from all sources about potential fraud, waste, abuse and mismanagement in Department of Health & Human Services programs. The reporting individual should indicate that the fraud, waste and/or abuse concerns an SBIR/STTR grant or contract, if relevant. Report Fraud.
Cooperative Agreement Terms and Conditions of Award
Not Applicable
NIH requires that SBIR/STTR grantees submit the following reports within 90 days of the end of the grant budget period unless the grantee is under an extension. When multiple years are involved, awardees will be required to submit the Research Performance Progress Report (RPPR) annually and financial statements as required in the NIH Grants Policy Statement.
Failure to submit timely final reports may affect future funding to the organization or awards with the same PD/PI.
For details about each specific required report, see Part III. Section 5, "SBIR/STTR Award Guidelines, Reporting Requirements, and Other Considerations," in the Supplement Grant Applications For All Competing Applications and Progress Reports.
The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.
In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts from all Federal awarding agencies with a cumulative total value greater than $10,000,000 for any period of time during the period of performance of a Federal award, must report and maintain the currency of information reported in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently FAPIIS). This is a statutory requirement under section 872 of Public Law 110-417, as amended (41 U.S.C. 2313). As required by section 3010 of Public Law 111-212, all information posted in the designated integrity and performance system on or after April 15, 2011, except past performance reviews required for Federal procurement contracts, will be publicly available. Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75 – Award Term and Conditions for Recipient Integrity and Performance Matters.
We encourage inquiries concerning this funding opportunity
and welcome the opportunity to answer questions from potential applicants.
Customer Support (Questions regarding Grants.gov registration and
submission, downloading forms and application packages)
Contact Center Telephone: 800-518-4726
Email: firstname.lastname@example.com
GrantsInfo (Questions regarding application instructions and
process, finding NIH grant resources)
Email: email@example.com (preferred method of contact)
Telephone: 301-710-0267
eRA Service Desk (Questions regarding ASSIST, eRA Commons
registration, submitting and tracking an application, documenting system
problems that threaten submission by the due date, post submission issues)
Finding Help Online: http://grants.nih.gov/support/ (preferred method of contact)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)
SBA Company Registry (Questions regarding required
registration at the SBA Company Registry and for technical questions or issues)
Website to Email: http://sbir.gov/feedback?type=reg
Lorenzo M. Refolo, PhD
National Institute on Aging (NIA)
Telephone: 301-594-7576
Email: firstname.lastname@example.com
Partha Bhattacharyya, Ph.D.
National Institute of Aging (NIA)
Division of Behavioral and Social Research (DBSR)
Telephone: 301-496-3138
Email: email@example.com
Chhanda Dutta, PhD
National Institute on Aging (NIA)
Division of Geriatrics and Clinical Gerontology (DGCG)
Email: firstname.lastname@example.com
Michael-David ARR Kerns, M.M., M.S., Ph.D.
National Institute on Aging (NIA)
NIA SBIR-STTR Program Coordinator
Telephone: 301-402-7713
Email: firstname.lastname@example.com
Examine your eRA Commons account for review assignment and contact information (information appears two weeks after the submission due date).
Richard Proper
National Institute on Aging (NIA)
Telephone: 301-402-7735
Email: firstname.lastname@example.com
Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Part 75.
The STTR Program is mandated by the Small Business Reauthorization Act of 1997 (P.L. 105-135), and reauthorizing legislation, P.L. 107-50 and P.L. 112-81 (SBIR/STTR Reauthorization Act of 2011). The basic design of the NIH STTR Program is in accordance with the Small Business Administration (SBA) STTR Policy Directive.
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.


text:
- Home
- Products
- About us
- Knowledgebase
- Ship Chandler
- Jobs & Career
- Contact us
- Product FAQ
- Registration
Industry >> Plastics
RX MARINE INTERNATIONAL is most popular chemicals source in INDIA, Keeping ready stock at 5 LOCATION which includes Mumbai, Kandla - Gandhidham, Vizag - Visakhapatnam, Ennore - Chennai, Kolkata more then 3000 types of chemicals. Please click here to get PRODUCT Categories details http://rxmarine.com/Products
Mail Us for any PRODUCT related information and purchase inquiry : firstname.lastname@example.com ( This mail is for customer / Buyer only ) And if you wants to add your hand as a supplier, And if you have volume manufacturing capacity of chemicals, pl. drop your mail at email@example.com ( This mail is for supplier only )


text:
McDaniel GM SuperStore
1065 Mt. Vernon Ave.
Marion, OH 43302
Stressful events can happen such as mechanical breakdowns, your vehicle being stolen or totaled,
and the inevitable dents and dings. These are just a few examples of vehicle mishaps that can result
in hundreds, if not thousands, of dollars in unforeseen costs when not covered by the original
warranty or your auto insurance. You can offset many of these unexpected expenses with our suite
of vehicle protection products.
Repair costs increase every year and can add up to thousands of dollars depending on the vehicle part or service required. A Vehicle Service Contract (VSC) can take over where your manufacturer's warranty ends. It can help protect you from unexpected expenses, plus provides for a variety of other convenient benefits.
If your vehicle is stolen and not recovered, totaled in an accident, or damaged beyond repair due to a natural disaster, your auto insurance alone may not pay the remaining balance on your vehicle loan. This could leave a financial "gap" of thousands of dollars. In the event of a total loss, Guaranteed Auto Protection can waive or cancel the remaining balance of your vehicle loan after the payment from your insurance company.
Whether you drive on city or country roads, you are likely to face a variety of hazards from potholes to nails, broken glass and other road debris. The Tire & Wheel plan gives you unlimited protection from these hazards as well as emergency roadside assistance.
Nothing looks worse on your new car than the damage caused by tree sap, road salt, bird waste and other environmental elements. The protective sealant applied to your vehicle's exterior can help keep it looking showroom new. On the interior, your leather and fabric can be protected from food spills, makeup, chewing gum, and even pet stains.
Your new car will inevitably get bumped and banged by other car doors, wildly thrown balls, runaway shopping carts, and garage hazards like bicycles and lawn mowers. You can have those dents and dings removed from the exterior metal panels with Paintless Dent Repair.
Want the flexibility to choose the protection that fits your driving needs and budget? Then Select Protection is for you. A plan can be customized to include options such as Tire & Wheel Protection, Alloy Wheel Cosmetic Repair, Windshield Repair and Paintless Dent Removal. You also automatically receive Emergency Roadside Service. Select Protection can help keep your vehicle looking new, maintain its value, and reduce your ownership worries.
Losing your car key is not only stressful, but also expensive. Key fobs are more high tech than ever, and replacing and programming a new one can cost up to $500 or more depending on the car make and model. ** Key Replacement protection can pay to replace your lost, stolen or damaged key fobs and other covered keys.
The cost of routine maintenance is an expense no one likes. Oil changes, chassis lubrication, tire rotation, and overall inspection of fluids, brakes, the battery and more are critical. Keeping up with regular maintenance can help ensure your vehicle is running in top condition and avoid major repairs. Select from a variety of Maintenance Plans to cover the cost of routine maintenance. Emergency Roadside Assistance is included with every plan.
Vehicle upkeep can add up quickly—burned out headlamps, worn windshield wiper blades, faulty fuses, cracked drive belts, just to name a few. A Select Care Plan can give you coverage for parts that often need to be replaced, but are typically excluded from manufacturer's warranties, maintenance plans and vehicle service contracts. This no-deductible plan also provides Emergency Roadside Service, rental car reimbursement and trip interruption insurance.
Did you know that a vehicle is stolen every 45 seconds in the United States?* You can help protect yourself from being one of these statistics with Universal Security Guard® theft deterrent. Retro-reflective labels are applied to key areas of your car to warn thieves that your vehicle is protected with an anti-theft system. If your car is stolen, this protection can help offset the cost of theft-related expenses such as your insurance policy deductible and rental car reimbursement.
Driving your leased vehicle will likely result in normal wear and tear such as paint chips, exterior scratches, interior fabric stains, and more. Did you know when your lease ends, you can be held responsible for the condition of your vehicle? With Lease Wear & Use protection, up to $5,000 of repair charges may be covered. This no-deductible protection helps reduce the worry about out-of-pocket expenses at lease end.
Learn more about protection
plan terms and pricing.
Want to find out more about one or more of our vehicle protection products? Please provide the information below and a representative from our dealership will contact you directly.
for your interest in McDaniel GM SuperStore and our Vehicle Protection
Products. Your request has been received and a member of our
dealership team will contact you shortly.
Please contact us at 740-389-6335 with any questions.
McDaniel GM SuperStore


text:
Our Cabin in the Mountain candle smells like a breath of fresh air. Notes of cedar wood, blue spruce and mint, this candle was inspired by our favourite place- the mountains.
• Made with 100% natural soy wax, lead-free cotton wicks, and premium essential and perfume grade oils.
• 8.5oz
• Always hand poured in Saskatoon, Saskatchewan. ♡
All sales final.
You have two weeks from the date of your purchase to return. Receipts are not required as we store purchase info. If you ordered online and selected Local Pickup, you have two weeks from the date that your order was ready for pickup, not the date you picked it up. Please visit the store to process your return.
Online Returns:
You have two weeks from the date your order was marked as delivered by the courier company. If you choose an untracked method of shipping, you have two weeks from the shipment date. All online returns need to be authorized by clicking HERE. Return instructions will then be emailed to you. You have FIVE days from the date of your return request to drop your package at the post office. Once your package has been received you will receive an email with your store credit information within three days of us receiving your package. Returns that are received late will be denied or have a 20% restocking fee applied.
If you are returning items from an order that took advantage of a Free Shipping offer, $11.99 will be deducted from your return in the event that your order total drops below the $130 dollars required.
Please visit our store for exchanges. We do not offer exchanges online. You are welcome to repurchase the item in the correct size once you receive your store credit.
Damaged Items:
We thoroughly inspect items before sending them out but in the event that you do have something arrive damaged, please let us know within 3 days of receiving your order to receive a replacement or a refund. Damages caused by cutting open your package or removing hang tags will not be accepted.
Order Cancellations:
Orders cannot be cancelled after they are placed. We reserve inventory and start the order process immediately and as such, we are unable to cancel orders once they have been placed.
***If more than $800 of returns are made within a calendar year, a 20% restocking/handling fee will be deducted from each return moving forward. We do our best to help you decide on the size you need before ordering by providing measurements in the product description of each item. Please reach out to our support team before ordering multiple sizes of one item so we can help you get the best fit. Effective June 24, 2021**